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IMPORTANCE Numerically, the most important genetic risk factor for the development of
Parkinson disease (PD) is the presence of a glucocerebrosidase gene (GBA) mutation.
OBJECTIVE To evaluate longitudinally and clinically a GBAmutation–positive cohort and the
evolution of the prodromal features of PD.
DESIGN, SETTING, AND PARTICIPANTS Participants in a study of the etiology and prodrome of
PDwere reevaluated in this clinic-based 2-year follow-up report. Patients with type 1 Gaucher
disease (GD) and heterozygous GBAmutation carriers were recruited in 2010 from the
Lysosomal Storage Disorder Unit at the Royal Free Hospital, London, England. Thirty patients
who previously received a diagnosis of type 1 GD, 28 heterozygous GBAmutation carriers,
and 26 genetically unrelated controls were included. Exclusion criteria included a diagnosis of
PD or dementia for both the patients with GD and the GBAmutation carriers and any existing
neurological disease for the controls.
MAIN OUTCOMES ANDMEASURES Assessment was performed for clinical markers using
standardized scales for hyposmia, rapid eyemovement sleep behavior disorder, depression,
autonomic dysfunction, cognitive function, and parkinsonianmotor signs (using the Unified
Parkinson’s Disease Rating Scale motor subscale [UPDRS part III]).
RESULTS Over 2 years, depression scores were significantly worse for heterozygous carriers
(mean baseline, 0.65; mean follow-up, 2.88; P = .01), rapid eyemovement sleep behavior
disorder scores were significantly worse for patients with GD (mean baseline, 0.93; mean
follow-up, 2.93; P < .001) and heterozygotes (mean baseline, 0.10; mean follow-up, 2.30;
P < .001), and UPDRS part III scores were significantly worse for patients with GD (mean
baseline, 4.29; mean follow-up, 7.82; P < .001) and heterozygotes (mean baseline, 1.97; mean
follow-up, 4.50; P < .001). For controls, there was a small but significant deterioration in the
UPDRS part II (activities of daily living) score (mean baseline, 0.00; mean follow-up, 0.58;
P = .006). At 2 years, olfactory and cognitive assessment scores were lower in patients with
GD and heterozygotes compared with controls, but they did not differ significantly from
baseline. When the results from the patients with GD and the heterozygotes were combined,
a significant deterioration from baseline was observed, as reflected in the Rapid Eye
Movement Sleep Behaviour Disorder Questionnaire (mean baseline, 0.51; mean follow-up,
2.63; P < .001), Beck Depression Inventory (mean baseline, 1.72; mean follow-up, 4.44;
P = .002), and UPDRS part II (mean baseline, 0.88; mean follow-up, 2.01; P < .001) and part
III scores (mean baseline, 3.09; mean follow-up, 6.10; P < .001) (all P < .01), and at 2 years,
significant differences in University of Pennsylvania Smell Identification Test, Unified Multiple
System Atrophy Rating Scale, Mini-Mental State Examination, Montreal Cognitive
Assessment, and UPDRS part II and part III scores were observed between patients with
GD/heterozygotes and controls (all P < .05).
CONCLUSIONS AND RELEVANCE This study indicates that, as a group,GBAmutation–positive
individuals show a deterioration in clinical markers consistent with the prodrome of PD.
Within this group of individual, 10% appear to be evolving at a more rapid rate.
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H omozygous GBA mutations cause Gaucher disease(GD), a lysosomal storage disease. It is presently esti-mated that homozygous or heterozygous GBAmuta-
tions confer a 20- to 30-fold increased risk for Parkinson dis-
ease (PD),1,2 and at least 7% of patients with PD have GBA
mutations.2,3 The percentage is higher among the Ashkenazi
Jewish population.4 The percentage of GBA mutation carri-
erswhodevelopPDhasbeenestimated tobe 13.7%at 60years
of age and 29.7% at 80 years of age,5 and so a method to de-
termine individual risk for PD expression in this population
wouldbeveryvaluable. In addition, thosewithdementiawith
Lewybodies are8 timesmore likely to carry amutation inGBA
than healthy controls, which suggests a role for GBA muta-
tions in other Lewy body disorders.6
For any neuroprotective treatment or disease-modifying
therapy to bemost effective, PD shouldbedetected at as early
a stage as possible. The deposition of α-synuclein is not re-
stricted to the brain; for example, deposits have been found
in the olfactory bulb, the peripheral nervous system, the en-
teric nervous system, theheart, and thepelvic plexuses.7 This
pathology probably underlies the early nonmotormanifesta-
tions of PD, which may precede the onset of more typical PD
motor symptoms by several years.8
Candidate biomarkers have been proposed and may be
useful objective measures for the early detection of PD.9,10 In
our study, we have used early clinical markers to quantify
nonmotor symptoms such as hyposmia, rapid eye movement
sleep behavior disorder, depression, cognition, and auto-
nomic dysfunction.
The aim of our study was to provide longitudinal data on
a GBA-positive cohort at high risk for the development of PD
and to identify biomarkers or symptoms indicating progres-
sion to early PD. The first clinical evaluationof this cohort has
beenpublished,11 and the results presentedhere represent the
2-year follow-up.
Methods
Participants
Patientswith type1GDwererecruited fromtheLysosomalStor-
age Disorder Unit at the Royal Free Hospital in London, En-
gland, in 2010. Potential heterozygousGBAmutation–positive
relatives (78.6%ofparents, 10.7%of siblings, and 10.7%of chil-
dren>21yearsofage)andgeneticallyunrelatedcontrols (spouses
or partners) were identified by obtaining a detailed family his-
tory from each patient with GD, and these heterozygotes and
controlswere then recruited toparticipate inour study.Partici-
pantswerealso recruited fromtheUKGauchersAssociation. In
all, this unique cohort included 135participants.Among them,
90participantshavebeen followedup longitudinally,with tar-
get follow-upassessmentsat 2-year intervalsbeginning in2012.
Exclusioncriteria includedadiagnosisofPDordementiaforboth
thepatientswithGDandtheGBAmutationcarriers andanyex-
istingneurologicaldisease for thecontrols.ThediagnosisofPD
wasmadeaccordingtotheUKParkinson’sDiseaseSocietyBrain
BankCriteria.12Dementiawasdiagnosedaccording toDiagnos-
tic and Statistical Manual of Mental Disorders (Fourth Edition)
criteria for patients with a Mini-Mental State Examination
(MMSE) score of 24 or less. TheGBAmutation status in all par-
ticipantswasconfirmedbySanger sequencingof theGBAgene,
aspreviouslydescribed.11 The senior researcherwasblinded to
genotype. Our study was approved by the Hampstead Re-
search Ethics Committee (reference 10/H0720/21). All partici-
pants providedwritten informed consent.
Follow-up Evaluation
Of the 90 participants who were evaluated at baseline
(2010-2011),114 (4.4%)were lost tofollow-upbecausetheyeither
declined toparticipate (n = 2)or couldnotbecontacted (n = 2).
In addition, 2 participants (2.2%) died (one died of pneumo-
nia, and theotherdiedof breast cancer). Therefore, 84partici-
pants (93.3%) (30participantswhopreviously receivedadiag-
nosisof type 1GD, 28heterozygousGBAmutationcarriers, and
26 controls) completed the follow-up evaluation that com-
priseda structuredclinicalworkup, a standardizedclinicalhis-
tory, and a complete neurological assessment, which in-
cluded the use of theUnified Parkinson’s Disease Rating Scale
foractivitiesofdaily livingandthemotorsubscale (UPDRSparts
II and III, respectively), the University of Pennsylvania Smell
Identification Test (UPSIT) for olfactory function, the MMSE
and the Montreal Cognitive Assessment (MoCA) for cognitive
function, the Rapid Eye Movement Sleep Behaviour Disorder
Questionnaire (RBDQ), theBeckDepression Inventory (BDI) for
depression, and a subscale of the UnifiedMultiple SystemAt-
rophyRating Scale (UMSARS) for autonomic dysfunction. An-
osmiawas interpreted using age- and sex-adjusted normative
scores (http://sensonics.com/). All participants were exam-
ined independently by a physician trained in movement dis-
orders (M.B.).All procedureswereperformedandscored iden-
tically at follow-up to those performed at baseline. A senior
neurologistwho is anexpertonmovementdisorders (A.H.V.S.)
evaluated participants whenever there was a significant dif-
ference between follow-up and baseline UPDRS scores.
Statistical Analysis
The data were analyzed using IBM SPSS Statistics version 21.
Toassess thedifferencesbetweenthegroupmeanvaluesacross
the 2 different time points, we performed a 2-way analysis of
covariancewiththefactors“group”(eg,patientswithGDvscar-
riers vs controls) and “time” (time 1 vs time 2). The covariates
age, sex, education, and family relationshipwere added to the
designmatrix inorder to account fordifferences in thesemean
values between the groups. Post hoc tests were used to com-
pare the groups at follow-up. Paired t tests were used to com-
pare the scores within each group before and after follow-up.
Differences in age, sex, and ethnicity between groups were
checked using the 1-way analysis of variance and the χ2 test.
We also accounted for performing multiple statistical tests
across our dependent variables (the UPSIT, UMSARS, RBDQ,
MMSE, MoCA, UPDRS part II, UPDRS part III, and BDI scores)
bydefiningasignificancethreshold forstatistical testsofP < .05
andbycorrecting this formultiple comparisonsusing theBen-
jamini-Hochberg false discovery rate. In brief, this procedure
involves ordering allP values in ascending order and applying
a sequential threshold.
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Results
The 84 participants (40 men [47.6%]) had a mean (SD) fol-
low-up duration of 1.9 (0.2) years (range, 1.5-2.3 years). The
demographic, clinical, and genetic characteristics, alongwith
statistical comparisons, of the cohort are shown inTable 1. The
participantswith type 1GDdidnotdiffer significantly fromthe
heterozygous GBAmutation carriers or the controls in terms
of age, sex, and ethnicity (all P > .05, determined by use of
1-way analysis of variance and the χ2 test). Both the patients
with type 1 GD and the heterozygous GBA mutation carriers
were significantlymore likely than the controls tohave a fam-
ily history of PD (P = .03). As described previously,11 themost
common genotype in patients with type 1 GD was N370S/
L444P(11of30patients [36.7%]).Noneof thepatientswith type
1 GD had features of type III GD (such as generalized seizures
or progressivemyoclonic epilepsy). For the carriers, themost
common genotype was N370S (14 of 28 carriers [50.0%]).
GBAMutation–Positive Individuals
With Significant Deterioration
The scoreswith regard to theprodromal clinical features of PD
at baseline and follow-up are reported in Table 2 (see also
Figure). Please refer toTable2 for theexactPvalues.Therewas
asignificantdeterioration forGDpatientsover themean2years
of follow-up as reflected in the RBDQ, UPDRS part II, and
UPDRS part III scores. Over the same period, the GBA muta-
tion carriers showed a significant deterioration as reflected in
theRBDQ,UPDRSpart II,UPDRSpart III, andBDI scores.There
wasamarginalbutsignificantdeteriorationonly inthematched
controls with regard to the UPDRS part II score. There was
no difference between baseline and follow-up scores for all
groups for assessments of olfaction, cognition, and auto-
nomic dysfunction.
At the 2-year follow-up, the patients with GD showed a
significant difference in mean UPSIT, MMSE, MoCA, UPDRS
part II, and UPDRS part III scores when compared with con-
trols. Similarly, at 2 years, GBA mutation carriers showed
a significant difference in mean follow-up UPSIT, MMSE, and
MoCA scores when compared with controls. When the
patients with GD and the GBA mutation carriers were com-
pared at baseline, there was a significant difference in the
mean BDI score. At the 2-year follow-up, the patients with GD
demonstrated significantly worse mean BDI, UPDRS part II,
and UPDRS part III scores compared with the carriers. There
was no significant difference inmean UPSIT, UMSARS,MMSE,
MoCA, or RBDQ scores between the patients with GD and the
carriers at follow-up.
When the results from individuals with homozygous or
heterozygous mutations in GBAwere combined in a second-
ary, pooled analysis (Table 3; eFigures 1 and 2 in the Supple-
ment), a significantdeterioration inGBAmutation–positive in-
dividuals over the 2 years of follow-upwas foundwith regard
tomeanRBDQ, BDI, UPDRSpart II, andUPDRSpart III scores.
At baseline, GBA mutation–positive individuals showed sig-
nificant differences in mean UPSIT and MoCA scores when
compared with controls.11 At the 2-year follow-up, GBA mu-
tation–positive individuals showed significant differences in
mean UPSIT, UMSARS, MMSE, MoCA, UPDRS part II, and
UPDRS part III scores when compared with controls.
Specific PatientsWith GD andGBAHeterozygotes
With ParkinsonianMotor Signs and Significant Deterioration
At baseline, 3 patients with GD had parkinsonianmotor signs,
but this was insufficient for a diagnosis of PD. As described
previously,11 patient GD05 (male, 78 years of age, and Ashke-
nazi Jewish) had bilateral rigidity with activation maneuver,
asymmetric bradykinesia of all limbs, and gait impairment.
Patient GD18 (male, 83 years of age, and Ashkenazi Jewish)
had a left-arm rest tremor and bilateral arm rigidity with acti-
vation maneuver. Patient GD27 (male, 69 years of age, and
white British) had flexed posture, bilateral rigidity, and pos-
tural and kinetic tremor of the upper limbs. At follow-up, the
parkinsonian signs present at baseline in these patients had
worsened but did not meet the diagnostic criteria for PD.13
Patient GD05 had developed a tremor in both hands (inter-
mittent, present at rest, and worse on intention). Patient
Table 1. Demographic, Clinical, and Genetic Characteristics of the Study Cohorta
Characteristic
Patients With
Type 1 GD
(n = 30)
Heterozygous GBA
Mutation Carriers
(n = 28)
Controls
(n = 26) P Value
Age, mean (SEM), y 61.0 (2.1) 63.6 (2.0) 61.7 (2.2) .19b
Sex, No.
Male 14 12 14
.29c
Female 16 16 12
Ethnicity, No.
Ashkenazi Jewish 10 5 6
.38c
White British 20 23 20
Family history of PD, % 16.7 7.1 0.0 .03c,d
Most frequent genotype N370S/L444P N370S
GD treatment
ERT 25 0 0
SRT 2 0 0
None 3 0 0
Abbreviations: ERT, enzyme
replacement therapy; GD, Gaucher
disease; PD, Parkinson disease;
SRT, substrate reduction therapy.
a Significance was taken at the 5%
level.
bDetermined by use of 1-way analysis
of variance.
c Determined by use of the χ2 test.
d Significant difference.
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GD18 now had bilateral rigidity without activation maneuver
or gait impairment. Patient GD27 had developed a head
tremor, and the postural and kinetic tremor of his upper
limbs had worsened (now present at rest). In addition, 1
patient who did not have parkinsonian signs at baseline had
developed them at follow-up. Patient GD11 (male, 73 years of
age, and Ashkenazi Jewish) had developed a very slight
tremor of his right thumb (non–pill-rolling) present at rest
but with no other features of parkinsonism.
Similarly, 2 GBA carriers had parkinsonian motor signs
at baseline. As described previously,11 patient C17 (female,
78 years of age, and white British) had bilateral rigidity,
masklike facies, and bradykinesia, whereas patient C31
(male, 78 years of age, and white British) had masked facies,
bilateral rigidity with activation maneuver, left-arm kinetic
tremor, and flexed posture. At follow-up, the parkinsonian
signs present in these patients remained unchanged from
baseline.
When specific patients with GD and specific GBA hetero-
zygotes, both with features of parkinsonism (6 of 58 partici-
pants [10.3%]), were excluded, the follow-up data remained
significant. The remaining patients with GD and the remain-
ingGBAmutationcarriers (52of 58ofparticipants [89.7%]) still
showed a significant deterioration as reflected in the RBDQ,
UPDRS part II, UPDRS part III, and BDI scores after 2 years
(eTable 1 in the Supplement).
Table 2. Baseline and Follow-up Clinical Markers in a Group Comparison Between PatientsWith Type 1 GD, HeterozygousGBAMutation Carriers,
and Controlsa
Marker
Mean (SEM) Score Between-Group P Valueb
Patients With GD
(n=30)
Carriers
(n=28)
Controls
(n=26)
Patients With GD
vs Controls
Carriers
vs Controls
Patients With GD
vs Carriers
University of Pennsylvania Smell Identification Test score
Baseline 32.57 (0.96) 31.11 (0.93) 35.32 (0.40)
.003d .001d .52Follow-up 31.21 (0.98) 30.22 (1.10) 33.95 (0.62)
Within-group P valuec .03 .29 .13
Unified Multiple System Atrophy Rating Scale score
Baseline 0.40 (0.15) 0.37 (0.15) 0.08 (0.06)
.004d .02d .99Follow-up 0.63 (0.16) 0.53 (0.16) 0.13 (0.07)
Within-group P valuec .11 .59 .32
Rapid Eye Movement Sleep Behaviour Disorder Questionnaire score
Baseline 0.93 (0.31) 0.10 (0.10) 0.25 (0.14)
.04 .99 .23Follow-up 2.93 (0.55) 2.30 (0.40) 1.08 (0.30)
Within-group P valuec <.001d <.001d .07
Mini-Mental State Examination score
Baseline 29.23 (0.17) 29.23 (0.18) 29.28 (0.16)
.01d .03d .99Follow-up 28.40 (0.48) 28.63 (0.32) 29.50 (0.21)
Within-group P valuec .08 .05 .30
Montreal Cognitive Assessment score
Baseline 25.93 (0.53) 25.55 (0.58) 27.32 (0.23)
.001d .001d .99Follow-up 26.33 (0.75) 26.21 (0.57) 27.73 (0.26)
Within-group P valuec .07 .38 .20
Unified Parkinson’s Disease Rating Scale part II score
Baseline 1.45 (0.82) 0.33 (0.21) 0.00 (0.00)
<.003d .99 .009dFollow-up 2.72 (0.66) 1.33 (0.30) 0.58 (0.19)
Within-group P valuec .003c <.001c .006d
Unified Parkinson’s Disease Rating Scale part III score
Baseline 4.29 (1.45) 1.97 (0.65) 0.21 (0.17)
<.001d .04 .006dFollow-up 7.82 (1.91) 4.50 (0.75) 0.92 (0.37)
Within-group P valuec <.001d <.001d .06
Beck Depression Inventory score
Baseline 2.68 (1.78) 0.65 (0.41) 0.33 (0.33)
.04 .99 .03dFollow-up 5.84 (1.14) 2.88 (0.68) 0.58 (0.43)
Within-group P valuec .04 .01d .11
Abbreviation: GD, Gaucher disease.
a Significance was taken at the 5% level for all variables. Only values that
survivedmultiple comparisons with the false discovery rate procedure were
denoted significant. Reported P values compare themean (SEM) scores for
clinical markers within groups (baseline and follow-up) and between groups
(patients with type 1 GD, carriers, and controls) at follow-up.
b Two-way analysis of covariance with Bonferroni correction.
c Determined by use of paired t test.
d Statistically significant difference.
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Premotor Signs Present at Baseline That Could Predict
ParkinsonianMotor Signs
When the clinical markers of specific patients with GD (pa-
tients GD05, GD11, GD18, and GD27) and specificGBA hetero-
zygotes (patients C17 andC31), bothwith parkinsonianmotor
signs,were comparedwith thoseofGBAmutation–positive in-
dividuals without features of parkinsonism, there were sig-
nificant differences in age (P = .002) and cognition (P = .009)
at baseline (eTable 2 and3 in the Supplement). BaselineUPSIT
scores were also noted to be lower for those individuals with
featuresofparkinsonism,but thisdifferencedidnot reach sta-
tistical significance.
Figure. Clinical Markers Showing Progression inGBAMutation–Positive Individuals in a 2-Year Follow-up Study
37
36
35
34
33
32
31
30
29
28
27
UP
SI
T 
Sc
or
e
Patients
With GD
GBA Mutation
Carriers
Controls
UPSITA
1.0
0.8
0.6
0.4
0.2
0
UM
SA
RS
 S
co
re
Patients
With GD
GBA Mutation
Carriers
Controls
UMSARSB
29
28
27
26
25
24
23
M
oC
A 
Sc
or
e
Patients
With GD
GBA Mutation
Carriers
Controls
MoCAC
30.0
29.5
29.0
28.5
28.0
27.5
M
M
SE
 S
co
re
 Patients
With GD
GBA Mutation
Carriers
Controls
MMSED
Baseline Follow-up Baseline Follow-up
Baseline Follow-up Baseline Follow-up
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0
RB
DQ
 S
co
re
BD
I S
co
re
Patients
With GD
GBA Mutation
Carriers
Controls
RBDQE
8
7
5
6
4
3
2
1
0
Patients
With GD
GBA Mutation
Carriers
Controls
BDIF
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0
UP
DR
S 
Pa
rt
 II
 S
co
re
Patients
With GD
GBA Mutation
Carriers
Controls
UPDRS Part IIG
12
10
8
6
4
2
0
UP
DR
S 
Pa
rt
 II
I S
co
re
Patients
With GD
GBA Mutation
Carriers
Controls
UPDRS Part IIIH
Baseline Follow-up Baseline Follow-up
Baseline Follow-up Baseline Follow-up
P <.05
P <.05
P <.05
P <.05
P <.05
P <.05
P <.05
P <.05
Mean baseline and follow-up scores
for olfaction (A), autonomic
dysfunction (B), Montreal Cognitive
Assessment (MoCA) scores (C), and
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Parkinson’s Disease Rating Scale
(UPDRS) part II scores for patients
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controls. H, A statistically significant
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Error bars indicate SEM. BDI indicates
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Discussion
Our studywasdesigned to investigate theprogressionof clini-
cal biomarkers in a cohort of individuals at high risk for PD.
Our results demonstrate that clinical features associatedwith
premotorPDandmotor featuresofPDhavebothevolvedsince
the initial testing, and they support the hypothesis that some
GBAmutation–positive individuals within this cohort are ex-
hibiting clinical features of early neurodegeneration.
OlfactoryabnormalitiesarefoundinthosewithPDwithmu-
tations inGBA,14 but they are not a reported feature ofGDor its
treatment. It has been proposed that the earliest α-synuclein
changes occur in the dorsalmotor nucleus of the vagus and ol-
factory bulb,8 and evidence suggests that an impaired sense of
smell is not simply a consequence of aging but rather is a pro-
dromal phenomenon thatmaypredict PD.15 In the cohort stud-
ied, both patients with type 1 GD and heterozygous mutation
carrierswere, as a group, hyposmic at baseline.11 At 2 years, fol-
low-up olfactory scores for patients with GD and for heterozy-
gous carriers remained significantly lower than those reported
for controls, but they remainedunchanged frombaseline. This
could reflect the short lengthof the follow-upperiod, consider-
ing that olfactory impairmentmay progress slowly.
An impaired sense of smell does appear to correlate with
othermodalities in theprodromalphaseofPD (eg,RBD).16Ow-
ing to its high specificity and long latency to clinical disease,
RBD is one of the strongest clinical predictors of neurodegen-
erative disease and a potential prodromalmarker for preven-
tative therapy.17 The RBDQ carries a high sensitivity, and for
those individuals without existing neurological or sleep dis-
orders, it carries a high specificity and, therefore, represents
a good tool to detect individuals with RBD.18 We did identify
a significantly increased frequencyof symptomsofRBDat the
follow-up assessment in GBA mutation–positive individuals
comparedwith controls. It is arguable whether a score of 5 or
6 shouldbe the cutoff point for a scale that is structured tode-
terminewhether there is RBDornot. It should benoted, how-
Table 3. Baseline and Follow-up Clinical Markers in a Pooled Analysis Comparing AllGBAMutation–Positive
Individuals vs Controlsa
Marker
Patients With Type 1 GD and Heterozygous
GBAMutation Carriers
(n = 58)
Controls
(n = 26)
Between-Group P Value
(Controls vs Carriers)b
University of Pennsylvania Smell Identification Test score
Baseline 31.85 (0.67) 35.32 (0.40)
<.001dFollow-up 30.71 (0.73) 33.95 (0.62)
Within-group P valuec .02 .13
Unified Multiple System Atrophy Rating Scale score
Baseline 0.38 (0·11) 0.08 (0.06)
.001dFollow-up 0.58 (0·11) 0.13 (0.07)
Within-group P valuec .15 .32
Rapid Eye Movement Sleep Behaviour Disorder Questionnaire score
Baseline 0.51 (0.20) 0.25 (0.14)
.06Follow-up 2.63 (0.33) 1.08 (0.30)
Within-group P valuec <.001d .07
Mini-Mental State Examination score
Baseline 29.23 (0.12) 29.28 (0.16)
.002dFollow-up 28.51 (0.27) 29.50 (0.21)
Within-group P valuec .02 .30
Montreal Cognitive Assessment score
Baseline 25.7 (0.38) 27.32 (0.23)
<.001dFollow-up 26.3 (0.45) 27.73 (0.26)
Within-group P valuec .06 .20
Unified Parkinson’s Disease Rating Scale part II score
Baseline 0.88 (0.39) 0.00 (0.00)
.02dFollow-up 2.01 (0.36) 0.58 (0.19)
Within-group P valuec <.001d .006c
Unified Parkinson’s Disease Rating Scale part III score
Baseline 3.09 (0.75) 0.21 (0.17)
<.001dFollow-up 6.10 (0.95) 0.92 (0.37)
Within-group P valuec <.001d .06
Beck Depression Inventory score
Baseline 1.72 (0.94) 0.33 (0.33)
.09Follow-up 4.44 (0.71) 0.58 (0.43)
Within-group P valuec .002d .11
Abbreviation: GD, Gaucher disease.
a Significance was taken at the 5%
level for all variables. Only values
that survivedmultiple comparisons
with the false discovery rate
procedure were denoted significant.
Reported P values compare the
mean (SEM) scores for clinical
markers within groups (baseline and
follow-up) and between groups
(controls and GBA
mutation–positive individuals) at
follow-up.
b Two-way analysis of covariance with
Bonferroni correction.
c Determined by use of paired t test.
d Statistically significant difference.
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ever, that the proportion of RBDQ scores greater than 5 was
higher amongGBAmutation–positive individuals thanamong
controls at follow-up, albeit this difference did not reach sig-
nificance (P = .39, determined by use of the χ2 test).
Depression can precede the onset of the motor symp-
toms of PD and is a presenting complaint in 12% to 22% of
patients.19 There was an increase in the number of reports of
depressive symptoms in GBA mutation–positive individuals
at follow-up. PatientswithGD can exhibitmoderate to severe
psychological complications, similar to patients with other
chronic illnesses.20 In addition, BDI scores of 1 to 10 are con-
sistentwithminimaldepression, and the specificityofdepres-
sion alone as a clinicalmarker of prodromal PD is lowbutmay
be usefully combined with other features.21
Mild cognitive impairment can occur as a prodrome to
parkinsonism22ordementiawithLewybodies.23Thereare sev-
eral lines of evidencenow for greater cognitive impairment in
thosewithestablishedGBA-relatedPDvs sporadicPD,24-26 and
thismay reflect a higher burdenof Lewybodydisease inGBA-
relatedparkinsonism.27,28 Interestingly, ina subgroupof6GBA
mutation–positive individualswithparkinsonianmotor signs,
mild cognitive impairment (MoCA score of ≤24 for 5 of 6 indi-
viduals [83.3%]) was themain premotor sign present at base-
line that couldhavepredicted theirmotordeterioration.Com-
pared with controls, the remaining GBA mutation–positive
individualsdemonstratedsignificantly lowerMMSEandMoCA
scores at follow-up, albeit these were unchanged from base-
line and still within the normal range for cognitive function.
ControlsshowedasmallbutsignificantchangeintheUPDRS
part II score frombaseline.Particular aspectsof theUPDRSpart
II thathadworsened for controls includedascoreof2.11 forget-
ting out of a bed, a car, or a deep chair; a score of 2.12 for walk-
ing (eg, use of awalking aid); and a score of 2.5 for dressing (eg,
help with buttons). Subjective complaints of stiffness, trem-
ors, and imbalanceareassociatedwithan increased risk for the
development of PD.29However,wenote that theUPDRSpart II
wasnotdesignedorvalidatedasa tool for activitiesofdaily liv-
ing for aging controls.We believe that what drove the changes
in thecontrolswasasmallgroupof individuals (n = 6)whowere
older (mean age, 70.5 years [range, 62.6-77.8 years]). A signifi-
cantlyhigher follow-upUPDRSpart II score forpatientswithGD
distinguished these individuals from age-matched controls.
There were some GBA mutation–positive individuals
(10.0%) with significant motor findings identified using the
UPDRSpart III thatdidnotoverlapwithnormalphysiology (eg,
bilateral postural tremor) or existing bone/joint abnormali-
ties. These individuals didnotmeet thediagnostic criteria for
PD but could represent a subgroup ofGBAmutation–positive
individuals who are progressing toward clinical PD.
We considered the effect of concurrentmedications. The
majority of patientswith type 1GD (83.0%)were receiving en-
zymereplacement therapy.This typeof therapydoesnot cross
the blood-brain barrier and has no reported neurological ad-
verse effects. Furthermore, enzyme replacement therapyhas
noknowneffectondysautonomia.Substrate reductiontherapy
can inducememoryproblems.30However, only2patientswith
GD were receiving substrate reduction therapy when evalu-
ated at baseline and at follow-up, and neither had cognitive
impairment.
To our knowledge, this study is the first to undertake the
longitudinal follow-up of a large cohort of GBA mutation–
positive individuals prior to the development of PD. Much of
the work published thus far in the literature has focused on
patients with established PD. This has been essential tomake
important comparisons between sporadic PD and GBA-
related parkinsonism and to observe subtle differences. The
opportunity toobservepatientsprospectivelywithin aunique
at-risk cohort such as this is essential for defining the optimal
time to intervene with neuroprotective therapy.
One limitation of our study was that not all investigators
were blinded to the genetic status of individuals. To mini-
mize any observer bias, standardized scores were used, and
all follow-up data were reexamined. Other potential criti-
cisms are the use of prodromal markers and their sensitivity,
specificity, and positive and negative predictive values. The
presence of clinical markers alone may be insufficient to ac-
curately predict a neurodegenerative disorder in themajority
of cases. However, clinical markers may be used in combina-
tion with other biochemical or imaging markers for prodro-
mal PD to develop a more reliable method for predicting PD.
Conclusions
The data from this cohort suggest that hyposmia is the earli-
est and most sensitive prodromal marker. Cognitive impair-
ment is also an early feature, and this may relate to the
increased cognitive impairment observed in GBA-related PD.
Symptoms of RBD, the most specific clinical marker, are now
present in GBA mutation–positive individuals. Depressive
symptoms have also surfaced but must be interpreted with
some caution, considering their low specificity as a marker
for PD. There has also, and perhaps most importantly, been a
significant decline on the UPDRS, which, together with
impaired RBD and depression, suggests that clinical markers
in some individuals of this GBA mutation–positive cohort
have evolved, in a pattern consistent with the clinical pro-
drome of PD.
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